Skip to main content

Table 2 Studies of the Cost-Effectiveness of Treatment for ADHD

From: A review of the economic burden of ADHD

Citation

Comparators

Study Design

Findings1

Gilmore & Milne 2001

MPH, placebo

• Decision analytic model assessing cost-utility

Cost per each additional QALY gained with MPH treatment (versus no treatment) ranged from $15,509 to $19,281 when considering short-and medium-term benefits of MPH. Cost per QALY gained ranged from $9,850–$59,101 in sensitivity analyses

Novartis data on file (2000; referenced in Lord & Paisley 2000)

MPH, placebo

• Decision analytic model assessing cost-utility

Cost per each additional QALY gained with MPH treatment (versus no treatment) was $27,766.

Zupancic et al. 1998

MPH, placebo

• Decision analytic model assessing cost-effectiveness

Cost per each additional point in the Conners Teacher Rating Scale gained with MPH treatment (versus no treatment) was $93, or $560 for a 6-point (1 SD) gain.

  1. 1All costs updated to Year 2004 US $ using the Medical Services component of the Consumer Price Index (for US-based studies). For non-US studies, all country-specific costs first updated to Year 2004 currency values based on country-specific inflators; and then converted to Year 2004 US$ based on currency exchange rates.
  2. MPH = methylphenidate
  3. QALY = quality-adjusted life years
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us